» Articles » PMID: 11463011

The Treatment of Multidrug-resistant Tuberculosis in Turkey

Overview
Journal N Engl J Med
Specialty General Medicine
Date 2001 Jul 21
PMID 11463011
Citations 49
Authors
Affiliations
Soon will be listed here.
Abstract

Background: We evaluated the results of treatment in 158 consecutive patients with multidrug-resistant tuberculosis who were treated at our center in Istanbul.

Methods: A total of 21 female patients and 137 male patients (age range, 15 to 68 years) received treatment for multidrug-resistant tuberculosis between March 1992 and October 1999. The patients had previously received a mean of 5.7 antituberculosis drugs and were infected with organisms that were resistant to a mean of 4.4 drugs. All patients were infected with organisms that were resistant to both isoniazid and rifampicin. The regimens we used were selected on the basis of previous treatment protocols and the results of susceptibility tests. All patients received at least three drugs thought to be active; the treatment was continued for at least 18 months after the conversion to a negative culture and for at least 24 months in the absence of first-line drugs.

Results: The mean number of drugs given during the study was 5.5 (range, 3 to 9). Surgical resection was performed in 36 patients. Adverse effects led to discontinuation of one or more drugs in 62 patients (39 percent). Cultures became negative in 150 patients (95 percent) after a mean of 1.9 months (range, 1 to 9). The overall success rate of treatment was 77 percent, with cures in 78 patients (49 percent) and probable cures in 43 (27 percent). Treatment failed in 13 patients (8 percent). Seven patients died (4 percent). Seventeen patients (11 percent) did not complete the treatment regimen. The patients with unsuccessful outcomes were older than those with successful outcomes (mean age, 42 years vs. 36 years; P=0.008), had received a larger number of drugs previously (median, six vs. five; P=0.048), were more likely to have been treated previously with ofloxacin (57 percent vs. 30 percent, P=0.004), and were less likely to have received ofloxacin as part of the study protocol (65 percent vs. 84 percent, P=0.018). Thirty-eight percent of the patients with unsuccessful outcomes were infected with organisms that were resistant to more than five drugs. In a step-down logistic-regression analysis, a successful outcome was independently associated with a younger age (P=0.013) and the absence of previous treatment with ofloxacin (P=0.005).

Conclusions: Most patients with multidrug-resistant tuberculosis can be cured with the use of appropriate, intensive treatment regimens.

Citing Articles

Unsuccessful treatment outcome and associated risk factors. A prospective study of DR-TB patients from a high burden country, Pakistan.

Massud A, Khan A, Syed Sulaiman S, Ahmad N, Shafqat M, Ming L PLoS One. 2023; 18(8):e0287966.

PMID: 37561810 PMC: 10414635. DOI: 10.1371/journal.pone.0287966.


Genetic Characterization Conferred Co-Resistance to Isoniazid and Ethionamide in Isolates from Southern Xinjiang, China.

Cao B, Mijiti X, Deng L, Wang Q, Yu J, Anwaierjiang A Infect Drug Resist. 2023; 16:3117-3135.

PMID: 37228658 PMC: 10204763. DOI: 10.2147/IDR.S407525.


Updated considerations in the diagnosis and management of tuberculosis infection and disease: integrating the latest evidence-based strategies.

Graciaa D, Schechter M, Fetalvero K, Cranmer L, Kempker R, Castro K Expert Rev Anti Infect Ther. 2023; 21(6):595-616.

PMID: 37128947 PMC: 10227769. DOI: 10.1080/14787210.2023.2207820.


At Long Last: Short, All-Oral Regimens for Multidrug-Resistant Tuberculosis in the United States.

Sinha P, Jacobson K, Horsburgh Jr C, Acuna-Villaorduna C Open Forum Infect Dis. 2023; 10(4):ofad177.

PMID: 37125228 PMC: 10135426. DOI: 10.1093/ofid/ofad177.


Prevalence of long-term physical sequelae among patients treated with multi-drug and extensively drug-resistant tuberculosis: a systematic review and meta-analysis.

Akalu T, Clements A, Wolde H, Alene K EClinicalMedicine. 2023; 57:101900.

PMID: 36942158 PMC: 10023854. DOI: 10.1016/j.eclinm.2023.101900.